<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100938">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02033759</url>
  </required_header>
  <id_info>
    <org_study_id>Anxiety &amp; Lymphedema</org_study_id>
    <nct_id>NCT02033759</nct_id>
  </id_info>
  <brief_title>Patient Anxiety Associated With Lymphedema Surveillance Method</brief_title>
  <official_title>A Study of Patient Anxiety Associated With Lymphedema Surveillance: Comparing Volumetric Analysis and Bio-Impedance Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mercy Integrative Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mercy Integrative Medicine</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We propose to study the impact of BIA screening on anxiety and primary prevention strategies
      for lymphedema development among patients with recent surgery for breast cancer.  Currently,
      professional societies recommend scheduled follow-up visits to screen for lymphedema after
      recovery from breast cancer (e.g., 6-week, 3-month, 6-month visits with a certified
      lymphedema therapist).  Screening involves a discussion of lymphedema symptoms and risk
      reduction strategies, measurement of the affected limb with a tape measure, and physical
      inspection for physical changes consistent with lymphedema.  In the proposed study, patients
      will be randomly assigned to the addition of BIA screening vs. usual care.  At each
      screening visit, all patients will be assessed for their current lymphedema risk behaviors,
      as outlined by the National Lymphedema Network (7).  To evaluate anxiety levels, all
      patients will be asked to fill out the Beck Anxiety Inventory, a validated screening tool
      used in prior studies of patients with breast cancer (8,9).  This questionnaire will be
      administered at each follow-up lymphedema screening visit, and the baseline will be
      administered at the preoperative visit.  For patients randomly assigned to BIA screening,
      this involves the placement of adhesive electrodes on the each wrist and an ankle, followed
      by connection of the electrodes to the BIA machine, which then uses a painless electrical
      impulse to measure impedance of flow and thus asymmetry in the extracellular lymphedema
      volume between the 2 upper limbs (6,10).  Statistical analysis will involve comparison of
      lymphedema risk behaviors and anxiety levels between those patients with vs. without BIA
      screening.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening</study_design>
  <primary_outcome>
    <measure>Anxiety</measure>
    <time_frame>Pre-operative-6mos. post breast surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Numeric score on Beck Anxiety Inventory</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Upper Extremity Limb Volume</measure>
    <time_frame>at enrollment (pre-op), 6 weeks post-op, 3 and 6 months post-op</time_frame>
    <safety_issue>No</safety_issue>
    <description>Calculated in milliliters from circumferential measurements</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Bio-Impedance LDEX value</measure>
    <time_frame>pre-op, 6 weeks post op, 3 months and 6 months post-op</time_frame>
    <safety_issue>No</safety_issue>
    <description>LDEX reading (numeric) from device</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Anxiety</condition>
  <arm_group>
    <arm_group_label>Traditional circumferential measurements</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Traditional screening with volumetric analysis Patient Anxiety Questionnaire</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bio-Impedance Testing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Traditional Screening with Volumetric Analysis and Bio-Impedance Analysis Patient Anxiety Questionnaire</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bio-Impedance Testing</intervention_name>
    <description>Participants in the BIA Arm will also undergo bio-impedance testing with this device.</description>
    <arm_group_label>Bio-Impedance Testing</arm_group_label>
    <other_name>LTU-400 by Impedimed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Anxiety Questionnaire</intervention_name>
    <description>21 item questionnaire</description>
    <arm_group_label>Traditional circumferential measurements</arm_group_label>
    <arm_group_label>Bio-Impedance Testing</arm_group_label>
    <other_name>Beck Anxiety Inventory will be administered.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Traditional Circumferential Measurements</intervention_name>
    <arm_group_label>Traditional circumferential measurements</arm_group_label>
    <arm_group_label>Bio-Impedance Testing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women recently diagnosed with breast cancer Age 18 and older

        Exclusion Criteria:

          -  Those women undergoing neo-adjuvant chemotherapy

          -  Those women with a pacemaker
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sarah A Stolker, MSPT</last_name>
    <phone>314-540-2858</phone>
    <email>sarah@stolker.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Diane Radford, MD</last_name>
    <phone>(324)323-4234</phone>
    <email>diane.radford@mercy.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mercy Clarkson/Clayton</name>
      <address>
        <city>Ballwin</city>
        <state>Missouri</state>
        <zip>63011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laura Boekemeier, RN</last_name>
      <phone>636-256-5000</phone>
      <email>laura.boekemeier@mercy.net</email>
    </contact>
    <investigator>
      <last_name>Sarah A Stolker, MSPT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 9, 2014</lastchanged_date>
  <firstreceived_date>January 7, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mercy Integrative Medicine</investigator_affiliation>
    <investigator_full_name>Sarah Stolker, MSPT</investigator_full_name>
    <investigator_title>Physical Therapist</investigator_title>
  </responsible_party>
  <keyword>Lymphedema</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Lymphedema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
